HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment (Q34882099)

5 August 2017

1 reference

title

HER-2 in breast cancer--methods of detection, clinical significance and future prospects for treatment (English)

1 reference

5 August 2017

2

Pinder SE

1 reference

5 August 2017

5

Ellis IO

1 reference

5 August 2017

Rampaul RS

1

1 reference

5 August 2017

Gullick WJ

series ordinal

3

1 reference

5 August 2017

Robertson JF

series ordinal

4

1 reference

5 August 2017

language of work or name

1 reference

1 September 2002

1 reference

Critical Reviews in Oncology Hematology

5 August 2017

published in

1 reference

5 August 2017

volume

43

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

231-244

1 reference

A genetic model for colorectal tumorigenesis

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Lessons from hereditary colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

The neu oncogene encodes an epidermal growth factor receptor-related protein

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Molecular cloning and expression of an additional epidermal growth factor receptor-related gene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Heregulin induces tyrosine phosphorylation of HER4/p180erbB4

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Differential expression of alternatively spliced c-erbB-2 mRNA in primary tumors, lymph node metastases, and bone marrow micrometastases from breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

ERBB2 oncogene in human breast cancer and its clinical significance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

c-erbB-2 amplification in breast cancer: detection in formalin-fixed, paraffin-embedded tissue by in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Analysis of cerbB2 expression using a panel of 6 commercially available antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Circulating tumor markers in breast cancer: accepted utilities and novel prospects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Prognostic significance of serum c-erbB-2 protein in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

The value of mitotic counting in the assessment of prognosis and proliferation in human tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

c-erbB-2 oncoprotein expression in primary and advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

c-erbB-2 andras expression levels in breast cancer are correlated and show a co-operative association with unfavorable clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Prognostic significance of c-erbB-2 expression in node negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Vascular anatomy and organ-specific tumor growth as critical factors in the development of metastases and their distribution among organs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

HER-2/neu oncogene protein and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Laminin receptors for neurite formation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Should selection of adjuvant chemotherapy for patients with breast cancer be based on erbB-2 status?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

HER-2 as a Prognostic, Predictive, and Therapeutic Target in Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Stress pathways and heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Cardiac myocytes as targets for the action of peptide growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Epidemiology of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Use of transcriptional regulatory elements of the MUC1 and ERBB2 genes to drive tumour-selective expression of a prodrug activating enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Ligands for ErbB-family receptors encoded by a neuregulin-like gene

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Transductional efficacy and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intracellular single-chain antibody for ovarian cancer gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Intra-tumoral application of a heregulin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Development of anti-p185HER2 immunoliposomes for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Potent antitumour activity of a new class of tumour-specific killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

RETRACTED: 4,5-Dianilinophthalimide: a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Recommendations for HER2 testing in the UK.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900207-4

7 January 2021

10.1016/S1040-8428(01)00207-4

Identifiers

DOI

1 reference

5 August 2017

1 reference